Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide
oleh: Umesh Lingaraj, Kishan Aralapuram, Sreedhara Chikkanayakanhalli, Akila Vishwanathan, Mahesha Vankalakunti
| Format: | Article |
|---|---|
| Diterbitkan: | Wolters Kluwer Medknow Publications 2020-01-01 |
Deskripsi
Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.